139 related articles for article (PubMed ID: 22689211)
1. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
Crombet O; Lastrapes K; Zieske A; Morales-Arias J
Pediatr Blood Cancer; 2012 Aug; 59(2):333-4. PubMed ID: 22689211
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
4. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Deenik W; Beverloo HB; van der Poel-van de Luytgaarde SC; Wattel MM; van Esser JW; Valk PJ; Cornelissen JJ
Leukemia; 2009 Mar; 23(3):627-9. PubMed ID: 18987655
[No Abstract] [Full Text] [Related]
5. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
6. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
Clarke S; O'Reilly J; Romeo G; Cooney J
Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
[No Abstract] [Full Text] [Related]
7. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
8. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
Hagemeijer A; Graux C
Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
[TBL] [Abstract][Full Text] [Related]
9. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
10. ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case.
Kim HJ; Woo HY; Koo HH; Tak EY; Kim SH
Am J Hematol; 2004 Aug; 76(4):360-3. PubMed ID: 15282669
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
[No Abstract] [Full Text] [Related]
12. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Gruber F; Mustjoki S; Porkka K
Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
[TBL] [Abstract][Full Text] [Related]
14. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
[No Abstract] [Full Text] [Related]
15. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
16. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
[No Abstract] [Full Text] [Related]
17. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
18. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
Jentsch-Ullrich K; Pelz AF; Braun H; Koenigsmann M; Mohren M; Wieacker P; Franke A
Haematologica; 2004 May; 89(5):ECR15. PubMed ID: 15136244
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib.
Kantarjian H; Jabbour E; Grimley J; Kirkpatrick P
Nat Rev Drug Discov; 2006 Sep; 5(9):717-8. PubMed ID: 17001803
[No Abstract] [Full Text] [Related]
[Next] [New Search]